The YPEL5-PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples

Karl Vandepoele; Jan Philippé; Barbara Denys

doi:10.1016/j.lrr.2015.07.001

The YPEL5-PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples

Leuk Res Rep. 2015 Aug 6;4(2):51-4. doi: 10.1016/j.lrr.2015.07.001. eCollection 2015.

Authors

Karl Vandepoele¹, Jan Philippé², Barbara Denys¹

Affiliations

¹ Laboratory for Molecular Diagnostics-Hematology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
² Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium.

Abstract

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western adults. It was suggested that transcripts from a reciprocal trans-splicing event between YPEL5 and PPP1CB were present exclusively in CLL patients (more than 90%). Here we show that the YPEL5-PPP1CB fusion is not specific for CLL but is also detected in other hematological malignancies such as chronic myeloid leukemia, monoclonal B cell lymphocytosis or acute leukemia and also in normal samples. As such, it is unlikely that the YPEL5-PPP1CB fusion is a good drug target in CLL or a suitable target to monitor disease.

Keywords: Chronic lymphocytic leukemia; Trans-splicing; YPEL5–PPP1CB.